Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases

REFERENCES

1. 1.↵
   1. World Health Organization

   . WHO coronavirus disease (COVID-19) dashboard (COVID-19). [Internet. Accessed March 2, 2021.] Available from: covid19.who.int
2. 2.↵
   1. Communidad de Madrid. Department of Health

   . [Covid-19 data, Madrid community.] [Article in Spanish. Internet. Accessed March 2, 2021.] Available from: www.comunidad.madrid/sites/default/files/doc/sanidad/201016_cam_covid19.pdf
3. 3.↵
   1. Pollán M,
   2. Pérez-Gómez B,
   3. Pastor-Barriuso R,
   4. Oteo J,
   5. Hernán MA,
   6. Pérez-Olmeda M, et al.

   Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020 Aug 22;396:535–44.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Wu C,
   2. Chen X,
   3. Cai Y,
   4. Xia J,
   5. Zhou X,
   6. Xu S, et al.

   Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934–43.

   OpenUrlPubMed
5. 5.↵
   1. Franklin J,
   2. Lunt M,
   3. Bunn D,
   4. Symmons D,
   5. Silman A.

   Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007;66:308–12.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Sepriano A,
   2. Kerschbaumer A,
   3. Smolen JS,
   4. van der Heijde D,
   5. Dougados M,
   6. van Vollenhoven R, et al.

   Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020;79:760–70.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Listing J,
   2. Gerhold K,
   3. Zink A.

   The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53–61.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Hospital Universitario Ramon y Cajal. Comunidad de Madrid

   . [2018.] [Article in Spanish. Internet. Accessed March 2, 2021.] Available from: www.comunidad.madrid/sites/default/files/doc/sanidad/memo/memoria-2018_hramonycajal_ok.pdf
9. 9.↵
   1. Government of Spain. Department of Health

   . [National Health Survey of Spain 2017.] [Website in Spanish. Internet. Accessed March 1, 2021.] Available from: www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2017/encuestaResDetall2017.htm
10. 10.↵
    1. Cobo-Ibanez T,
    2. Descalzo MA,
    3. Loza-Santamaria E,
    4. Carmona L,
    5. Munoz-Fernandez S.

    Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish Registry Biobadaser 2.0. Rheumatol Int 2014;34:953–61.

    OpenUrl
11. 11.↵
    1. Monti S,
    2. Balduzzi S,
    3. Delvino P,
    4. Bellis E,
    5. Quadrelli VS,
    6. Montecucco C.

    Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79:667–8.

    OpenUrlFREE Full Text
12. 12.↵
    1. Filocamo G,
    2. Minoia F,
    3. Carbogno S,
    4. Costi S,
    5. Romano M,
    6. Cimaz R.

    Absence of severe complications from SARS-COV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol 2021 Jan 15 (E-pub ahead of print).
13. 13.↵
    1. Haberman R,
    2. Axelrad J,
    3. Chen A,
    4. Castillo R,
    5. Yan D,
    6. Izmirly P, et al.

    Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med 2020;383:85–8.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Pablos JL,
    2. Abasolo L,
    3. Alvaro-Gracia JM,
    4. Blanco FJ,
    5. Blanco R,
    6. Castrejon I, et al.

    Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 2020;79:1170–3.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Pablos JL,
    2. Galindo M,
    3. Carmona L,
    4. Lledó A,
    5. Retuerto M,
    6. Blanco R, et al; RIER Investigators Group

    . Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020;79:1544–9.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Freites Nuñez DD,
    2. Leon L,
    3. Mucientes A,
    4. Rodriguez-Rodriguez L,
    5. Font Urgelles J,
    6. Madrid García A, et al.

    Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:1393–9.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    Data from the COVID-19 Global Rheumatology Alliance Global Registry. [Internet. Accessed March 1, 2021.] Available from: rheum-covid.org/updates/combined-data.html
18. 18.↵
    1. Akalin E,
    2. Azzi Y,
    3. Bartash R,
    4. Seethamraju H,
    5. Parides M,
    6. Hemmige V, et al.

    COVID-19 and kidney transplantation. N Engl J Med 2020;382:2475–7.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. D’Antiga L.

    Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl 2020;26:832–4.

    OpenUrlPubMed
20. 20.↵
    1. Donato MF,
    2. Invernizzi F,
    3. Lampertico P,
    4. Rossi G.

    Health status of patients who underwent liver transplantation during the coronavirus outbreak at a large center in Milan, Italy. Clin Gastroenterol Hepatol 2020;18:2131–3.

    OpenUrlCrossRef
21. 21.↵
    1. An P,
    2. Ji M,
    3. Ren H,
    4. Su J,
    5. Kang J,
    6. Yin A, et al.

    Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan, China. Lancet 2020 Feb 27 [Preprint. Accessed March 1, 2021.] Available from: http://dx.doi.org/10.2139/ssrn.3543590
22. 22.↵
    1. Sawalha AH,
    2. Zhao M,
    3. Coit P,
    4. Lu Q.

    Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020;215:108410.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Russell B,
    2. Moss C,
    3. George G,
    4. Santaolalla A,
    5. Cope A,
    6. Papa S, et al.

    Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. Ecancermedicalscience 2020;14:1022.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Sfikakis PP,
    2. Boletis JN,
    3. Lionaki S,
    4. Vigklis V,
    5. Fragiadaki KG,
    6. Iniotaki A, et al.

    Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501–13.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Melet J,
    2. Mulleman D,
    3. Goupille P,
    4. Ribourtout B,
    5. Watier H,
    6. Thibault G.

    Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013;65:2783–90.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Qin C,
    2. Zhou L,
    3. Hu Z,
    4. Zhang S,
    5. Yang S,
    6. Tao Y, et al.

    Dysregulation of immune response in patients with with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71:762–8.

    OpenUrlCrossRefPubMed